AI, Fraud Crackdowns, and New Leadership: The Three Forces Reshaping Home-Based Care in 2026
AI, federal fraud enforcement, and new leadership are changing how home health or hospice agencies operate and how buyers assess risk. This article explains what Compassus, Bayada, Elara Caring, Freedom Senior Services, and LiveWell Partners reveal about the next phase of home-based care. Owners will learn how technology, compliance, payer performance, and management depth can affect EBITDA durability, sale price, and buyer underwriting. It also provides practical steps for preparing an agency for a future acquisition or strategic partnership with Senate Healthcare.
8/14/20267 min read
AI is moving from pilot programs into daily home health or hospice operations, while federal agencies are intensifying fraud prevention and enrollment controls. At the same time, new executives at major providers are pursuing more disciplined growth, M&A, technology adoption, and market density strategies.
Quick-Scan Summary
Who this is for
Owner-operators of home health or hospice agencies with $2 million to $10 million in annual revenue
Owners considering a sale, succession plan, or strategic partnership
Leaders preparing for deeper buyer underwriting and compliance review
Agencies evaluating whether technology investments can improve EBITDA durability
Key takeaways
AI is becoming an operational differentiator in referral intake, clinical decision support, documentation, and risk management.
The federal fraud crackdown is increasing enrollment, billing, documentation, and payment risk for home health or hospice agencies.
New leadership at larger providers signals continued buyer appetite, but growth strategies are becoming more selective.
Clean compliance and measurable technology adoption can protect sale price by making earnings more reliable and easier for a buyer to underwrite.
Senate Healthcare is the buyer and strategic partner evaluating home health or hospice agency acquisitions.
Three Forces Changing the Industry
The August 2026 Home Health Care News analysis identifies three forces moving together across home-based care:
AI and technology are scaling into core workflows.
Federal agencies are taking a more aggressive approach to fraud, waste, and abuse.
New CEOs are reshaping growth plans, service lines, M&A priorities, and operating models.
For owners of mid-sized agencies, these are not abstract industry trends. They affect how quickly referrals are accepted, how clinicians prioritize risk, how regulators view the business, and how buyers calculate a sustainable purchase price.
Force One: AI Is Becoming an Operating Capability
AI adoption is becoming more practical. The question is no longer whether an agency has experimented with AI. The more important question is whether technology produces measurable improvements without weakening clinical judgment, privacy, or documentation integrity.
Compassus and the intake bottleneck
The Home Health Care News report describes how Compassus used an AI-powered intake platform to address a familiar problem. Previously, staff manually reviewed referral packets that could contain 60 to 80 pages. They checked whether the patient was located within the service area, whether insurance coverage was appropriate, and whether the referral fit the agency’s capabilities.
The AI platform can review those documents within minutes. By screening zip code, insurance, and referral fit earlier, the agency can reduce rejected referrals and shorten the time between receiving information and making an admission decision.
For a $2 million to $10 million agency, the lesson is not that every owner must immediately purchase an expensive AI platform. The lesson is that referral friction has a measurable cost. Track:
Time from referral receipt to decision
Percentage of referrals rejected after initial acceptance
Intake labor hours per 100 referrals
Referral conversion rate by source
Revenue and contribution margin by referral channel
If technology reduces wasted intake time and improves conversion, the effect can reach EBITDA. It can also make the agency more attractive to a buyer because the process is documented, repeatable, and less dependent on one experienced intake employee.
Bayada and clinical decision support
The July 2026 Home Health Care News coverage of Bayada provides a second example. Bayada uses AI-enabled clinical decision-support tools to synthesize electronic medical record data and clinical documentation, helping care teams identify patients who may need faster follow-up or a change in the care plan.
Bayada president Justin Searle described the technology as a tool that supports clinicians rather than replacing them. In one example, a 75-year-old patient with kidney disease and heart failure gained 13 pounds in a short period. The technology flagged the patient as high risk, allowing the care team to coordinate with a cardiologist, reinforce weight monitoring, and increase check-ins. The patient’s condition improved, and the intervention avoided an unnecessary hospitalization.
For home health or hospice owners, the practical takeaway is to connect technology to outcomes. A buyer will not assign a premium simply because an agency uses an AI product. The value comes from evidence that the technology improves response time, reduces avoidable utilization, strengthens documentation, or increases staff capacity.
Force Two: Fraud Enforcement Is Raising the Cost of Risk
On May 13, 2026, CMS implemented a temporary nationwide enrollment moratorium affecting new Medicare home health agency and hospice enrollments. CMS states that the moratorium applies to initial applications and certain non-exempt changes in majority ownership. It is scheduled to remain in effect for six months and may be extended.
The moratorium does not automatically terminate existing enrolled providers. However, it changes the transaction environment. Owners considering a sale, ownership change, new branch, or expansion need to understand how enrollment rules could affect timing and structure.
The Home Health Care News analysis also reports that CMS recommended states consider Medicaid home-based care enrollment moratoria and that more than $1 billion in Medicaid payments was deferred in the broader enforcement environment. These developments increase uncertainty around payer participation, cash flow, and transaction execution.
For owners, compliance is no longer simply a regulatory obligation. It is part of the asset’s value.
A buyer will examine:
Provider enrollment records and ownership history
Medicare and Medicaid billing patterns
Clinical eligibility documentation
Denials, overpayments, and repayment activity
Audit history and corrective action plans
Survey results and unresolved deficiencies
Payer-specific margin and accounts receivable trends
A clean compliance record does not guarantee a premium multiple, but unresolved issues can create a valuation haircut, an escrow requirement, a lower upfront payment, or a retrade after the buyer completes due diligence.
Force Three: New CEOs Are Driving More Selective Growth
Leadership changes at major providers show that the market is still focused on expansion, but the strategy is becoming more disciplined.
The Home Health Care News report highlights:
Ananth Mohan at Elara Caring, where the company has discussed technology, high-acuity care, value-based care, and additional M&A. Ares and DaVita are investing in Elara Caring, adding financial and strategic resources to its next phase.
Dr. Brian Holzer at Freedom Senior Services, who described plans to become an aggressive M&A player while building density in existing states and expanding into new markets.
Stacie Bratcher at LiveWell Partners, who emphasized Midwestern market density, added services, payer expansion, and M&A opportunities.
For smaller owners, this leadership activity sends two signals. First, there is continued strategic interest in home health or hospice businesses with strong local operations. Second, buyers are likely to favor agencies that fit a clear geographic, service-line, or operational strategy.
An agency does not need to be perfect to attract buyer interest. It does need a credible explanation of where it fits, how it can transition, and what risks a buyer will inherit.
What These Forces Mean for Valuation
Consider an agency with $700,000 of supportable EBITDA.
The difference is $700,000 before considering debt, cash, working capital, taxes, or deal structure. These are illustrative scenarios, not guaranteed market prices. Actual multiples vary by service mix, geography, payer exposure, staffing, quality, growth, and buyer underwriting.
Technology alone does not create the spread. Technology combined with clean compliance and durable operations can reduce the buyer’s perceived risk. If an AI-supported intake process saves $100,000 in annual labor and improves referral conversion, that improvement could increase EBITDA. At a 5.5x multiple, an additional $100,000 of durable EBITDA represents approximately $550,000 in potential enterprise value.
The same principle applies to compliance. If a buyer believes documentation problems could lead to repayment exposure or service disruption, the buyer may reduce the EBITDA being underwritten or apply a lower multiple.
A Simple Self-Assessment
Metrics Owners Should Track Monthly
Owners preparing for a future sale should build a monthly operating dashboard. For Medicare Advantage and other payer-sensitive business, include:
Net reimbursement per completed visit by payer
Authorized visits compared with clinically ordered visits
Denials and appeal overturn rates
Authorization labor hours per 100 Medicare Advantage episodes
Days in accounts receivable by payer
EBITDA margin by payer
Revenue concentration by individual Medicare Advantage plan
Referral volume by payer and referral source
These metrics help management make better decisions today and give a buyer evidence that earnings are being actively managed.
An Owner Vignette
Consider an owner we will call David. His home health agency generates approximately $4.6 million in revenue, but he personally approves most referrals and resolves nearly every payer issue. His team has valuable clinical experience, yet the business has no reliable dashboard for referral conversion, denial trends, or payer-level margin.
David’s agency may still be attractive to a buyer. However, the buyer will likely underwrite transition risk, invest additional management resources, and apply greater scrutiny to the reported EBITDA.
By documenting intake, delegating operating decisions, tracking payer performance, and completing a compliance review, David can make the business easier to transfer. The objective is not to present a perfect agency. It is to show that the agency’s earnings and quality can continue after the owner exits.
Plain-Language Glossary
EBITDA: A common measure of operating profit before interest, taxes, depreciation, and amortization.
Due diligence: The buyer’s detailed review of financial, clinical, legal, staffing, payer, and compliance information.
Provider number: The identifier that allows an enrolled healthcare provider to bill Medicare or another payer.
Moratorium: A temporary pause on certain new enrollments or ownership changes.
Buyer underwriting: The process a buyer uses to decide which earnings are reliable, which risks exist, and what price and terms are justified.
Multiple: The number multiplied by EBITDA to estimate enterprise value.
Valuation haircut: A reduction in price caused by risk, weak documentation, concentration, or lower-quality earnings.
EBITDA durability: The likelihood that reported operating profit will continue after a transaction.
So what should you do now?
Measure intake time, referral conversion, rejected referrals, and labor cost before investing in new technology.
Run a focused compliance review of provider enrollment, clinical documentation, audits, surveys, and billing patterns.
Build a monthly payer dashboard that shows reimbursement, authorization performance, denials, accounts receivable, and EBITDA margin.
Reduce key-person dependence by giving your administrator and clinical leadership clear authority before pursuing a sale.
Senate Healthcare Is the Buyer
Senate Healthcare LLC is the buyer and strategic partner pursuing acquisitions of home health or hospice agencies. We are not a broker, agent, or advisor representing sellers. We evaluate opportunities directly and focus on preserving quality care while building sustainable operations and a stronger national platform.
Your agency does not need to be perfectly positioned today. If you are considering succession, a sale, or a strategic partnership, Senate Healthcare can evaluate the business, understand its operating risks, and explore a transition structure designed to reduce disruption and protect long-term care quality.
Learn more about our acquisition approach through Senate Healthcare’s agency exit strategy page, or review our 2026 due diligence readiness checklist. To begin a confidential conversation about a potential sale or partnership, visit www.senatehealthcare.com.
Resources:
Unlock Your 30-Minute Agency Succession Review
Maybe you're ready to expand your reach, or perhaps it's time to consider your legacy and the future of your business. Either way, it all begins with a conversation. Schedule a confidential, no-obligation call to explore what the future might hold for you and your business.
Complete the form, and we'll reach out for a chat...
© 2025 SENATE HEALTHCARE LLC.
ALL RIGHTS RESERVED
